Physician profile
Khalid Saeed
NPI 1114958956
$7,516.31
in general payments reported to CMS, 2019-2025
47 companies · $50.21 in 2025
The $50.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $998 · 2021: $1,987 · 2022: $2,118 · 2023: $1,157 · 2024: $203 · 2025: $50.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,378.57 | 2019-2025 | Benlysta, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $807.07 | 2019-2023 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $654.61 | 2019-2023 | Myrbetriq |
| Genzyme Corporation | $533.10 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $470.25 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $340.20 | 2019-2021 | |
| Pfizer INC. | $329.93 | 2019-2023 | |
| Amgen INC. | $319.59 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $313.92 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $309.75 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $273.80 | 2021-2023 | |
| Abbvie INC. | $171.41 | 2019-2022 | |
| Esperion Therapeutics, INC. | $136.06 | 2021 | |
| Eisai INC. | $130.24 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $126.63 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.